Aminosyn PF 7% Sulfite Free


Aminosyn®-PF 7%, Sulfite-Free, (an amino acid injection — pediatric formula) is a sterile, nonpyrogenic solution for intravenous infusion. Aminosyn®-PF 7% is oxygen sensitive. The formulation is described below:

Aminosyn-PF 7%
An Amino Acid Injection — Pediatric Formula
Essential Amino Acids (mg/100 mL)

Isoleucine 534
Leucine 831
Lysine (acetate)* 475
Methionine 125
Phenylalanine 300
Threonine 360
Tryptophan 125
Valine 452
* Amount cited is for lysine alone and does not include the acetate salt.

Nonessential Amino Acids (mg/100 mL)

Alanine 490
Arginine 861
L-Aspartic Acid 370
L-Glutamic Acid 576
Glycine 270
Histidine 220
Proline 570
Serine 347
Taurine 50
Tyrosine 44

Electrolytes (mEq/L)

Sodium (Na+) (mEq/L) None
Potassium (K+) (mEq/L) None
Chloride (Cl) (mEq/L) None
Acetate (C2H3O2–)a (mEq/L) 32.5
a From lysine acetate.

Product Characteristics

Protein Equivalent (Approx. grams/L) 70
Total Nitrogen (grams/L) 10.69
Osmolarity (mOsmol/L) 561
pH (range) 5.5 (5.0 to 6.5)

The formulas for the individual amino acids present in Aminosyn-PF 7% are as follows:

Essential Amino Acids

Isoleucine, USP C6H13NO2
Leucine, USP C6H13NO2
Lysine Acetate, USP C6H14N2O2 • CH3COOH
Methionine, USP C5H11NO2S
Phenylalanine, USP C9H11NO2
Threonine, USP C4H9NO3
Tryptophan, USP C11H12N2O2
Valine, USP C5H11NO2

Nonessential Amino Acids

Alanine, USP C3H7NO2
Glycine, USP C2H5NO2
Arginine, USP C6H14N4O2
L-Aspartic Acid C4H7NO4
L-Glutamic Acid C5H9NO4
Histidine, USP C6H9N3O2
Proline, USP C5H9NO2
Serine, USP C3H7NO3
Taurine C2H7NO3S
Tyrosine, USP C9H11NO3

The flexible plastic container is fabricated from a specially formulated polyvinylchloride. Water can permeate from inside the container into the overwrap but not in amounts sufficient to affect the solution significantly.

Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials.

Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period.

Related Drugs Index: